Hybridoma cell line g250 and its use for producing monoclonal antibodies

Abstract

The invention relates to a hybridoma cell line which is capable of producing the monoclonal antibody G250. Furthermore, the invention describes the method of employing such cell line for the production and manufacture of monoclonal antibody G250 as well as derivatives thereof such as chimeric and humanized G250 antibodies.

1 . Hybridoma cell DSM ACC 2526 which produces the monoclonal antibody G250.  
     
     
         2 . Cell derived from hybridoma cell DSM ACC 2526 which produces a G250 antibody.  
     
     
         3 . The cell according to  claim 2  which has been obtained by transfer of genetic material encoding antibody G250 or at least the antigenbinding site thereof into a receptor cell.  
     
     
         4 . The cell according to  claim 2  which produces a chimeric antibody, a humanized antibody, a fully humanized antibody, a bispecific antibody, a single chain antibody, or F(ab′) 2 , Fab′, or Fab antibody fragments.  
     
     
         5 . The receptor cell according to  claim 3  or  4  which is a prokaryotic cell.  
     
     
         6 . The cell according to  claim 5  which is an  E. coli  cell.  
     
     
         7 . The cell of  claim 3  or  4  which is a eukaryotic cell.  
     
     
         8 . The cell according to  claim 7  which is a yeast cell, a myeloma cell or a CHO-cell.  
     
     
         9 . A method of producing a G250 antibody comprising: cultivating a cell according to any one of claims  1 - 7  under suitable conditions, wherein the antibody is produced and obtaining the antibody from the cell and/or from the culture medium.  
     
     
         10 . The method according to  claim 8  used for producing a pharmaceutical formulation which comprises the G250 antibody as an active agent.  
     
     
         11 . The method according to  claim 10 , wherein the pharmaceutical formulation comprises the chimeric G250 antibody.  
     
     
         12 . The method according to  claim 10 , wherein the pharmaceutical formulation comprises the chimeric G250 antibody in radiolabeled form.  
     
     
         13 . The method according to  claim 10 , wherein the pharmaceutical formulation comprises a chimeric G250 antibody coupled to a cytokine such as IL-2, TNF and/or GM-CSF.  
     
     
         14 . Use of a cell according to any one of claims  1 - 7  for the manufacture of a G250 antibody.  
     
     
         15 . Use of a G250 antibody for the manufacture of an agent for eliciting a delayed immune response in cancer therapy.  
     
     
         16 . The use of  claim 15  in the treatment of renal cell carcinoma.  
     
     
         17 . The use of  claim 15  or  16  for the treatment of metastases after tumor surgery.